H. Bryan Jr. Brewer

H. Bryan Jr. Brewer's AcademicInfluence.com Rankings

H. Bryan Jr. Brewer

Philosophy

#3811

World Rank

#6097

Historical Rank

Logic

#1422

World Rank

#2170

Historical Rank

philosophy Degrees

Download Badge

Philosophy

H. Bryan Jr. Brewer's Degrees

Doctorate Medicine University of California, San Francisco

Why Is H. Bryan Jr. Brewer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

H. Bryan Jr. Brewer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) (10068)
Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition (2004) (6183)
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004) (6171)
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) (1993) (4130)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. (2004) (2191)
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. (1988) (1962)
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 (1999) (1479)
Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition (2004) (1315)
Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments (1994) (849)
PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway (2001) (833)
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis (2003) (815)
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. (2012) (779)
A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia (1995) (526)
Dysfunctional HDL and atherosclerotic cardiovascular disease (2016) (496)
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. (2011) (441)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. (2000) (435)
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. (2011) (418)
Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux (2002) (390)
Effect of ACAT inhibition on the progression of coronary atherosclerosis. (2006) (387)
The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis* (2003) (349)
Abnormal in vivo metabolism of apolipoprotein E4 in humans. (1986) (345)
The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. (1983) (338)
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. (2001) (337)
Triglyceride, high density lipoprotein, and coronary heart disease. (1993) (335)
Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. (2001) (321)
Familial apolipoprotein E deficiency. (1986) (299)
Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. (1985) (296)
Complementary Roles of Farnesoid X Receptor, Pregnane X Receptor, and Constitutive Androstane Receptor in Protection against Bile Acid Toxicity* (2003) (295)
The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. (1978) (289)
Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. (1999) (278)
The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice (2001) (261)
Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. (1994) (259)
Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. (1984) (244)
Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. (1975) (242)
Cellular Localization and Trafficking of the Human ABCA1 Transporter* 210 (2001) (242)
Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice* (1999) (236)
ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. (2001) (232)
Advances in the gas chromatographic analysis of amino acid phenyl- and methylthiohydantoins. (1972) (230)
The plasma lipoproteins. (1977) (230)
Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations Published, JLR Papers in Press, November 4, 2002. DOI 10.1194/jlr.M200414-JLR200 (2003) (230)
Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. (1982) (222)
High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase (1997) (221)
Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. (2000) (221)
Type III Hyperlipoproteinemia: Diagnosis, Molecular Defects, Pathology, and Treatment (1983) (221)
The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. (1994) (220)
A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. (2010) (218)
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. (2016) (218)
Human apolipoprotein A-I and A-II metabolism. (1982) (216)
New micromethod for measuring cholesterol in plasma lipoprotein fractions. (1977) (214)
Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). (1980) (213)
The effects of low cholesterol, high polyunsaturated fat, and low fat diets on plasma lipid and lipoprotein cholesterol levels in normal and hypercholesterolemic subjects. (1981) (207)
Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. (1972) (207)
Translation of High-Density Lipoprotein Function Into Clinical Practice: Current Prospects and Future Challenges (2013) (207)
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. (1998) (207)
Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. (1997) (204)
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. (2003) (196)
Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study (2019) (189)
PLASMA-TRIGLYCERIDES IN REGULATION OF H.D.L.-CHOLESTEROL LEVELS (1978) (189)
Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. (1993) (187)
Increasing HDL Cholesterol Levels. (2004) (181)
Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. (2004) (177)
Regulation and intracellular trafficking of the ABCA1 transporter. (2001) (175)
In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II. (1991) (174)
Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. (1978) (173)
Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. (1981) (173)
The ABCA1 Transporter Modulates Late Endocytic Trafficking (2004) (173)
Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. (1985) (168)
Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. (1999) (163)
Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. (1999) (160)
The Complete Amino Acid Sequence of Alanine Apolipoprotein (apoC-III), an Apolipoprotein from Human Plasma Very Low Density Lipoproteins (1974) (159)
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial (2015) (159)
The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver Published, JLR Papers in Press, July 16, 2005. DOI 10.1194/jlr.M500080-JLR200 (2005) (157)
Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway Published, JLR Papers in Press, January 16, 2003. DOI 10.1194/jlr.M200475-JLR200 (2003) (155)
Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome (1993) (154)
Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. (1995) (153)
Isolation and characterization of apolipoproteins A-I, A-II, and A-IV. (1986) (152)
Human chylomicron apolipoprotein metabolism. (1978) (147)
Human liver apolipoprotein B-100 cDNA: complete nucleic acid and derived amino acid sequence. (1986) (146)
Activation of human post heparin lipoprotein lipase by apolipoprotein H (beta 2-glycoprotein I). (1980) (144)
Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase-deficient Mice* (2001) (140)
Overexpression of Human Lecithin Cholesterol Acyltransferase Leads to Hyperalphalipoproteinemia in Transgenic Mice (*) (1995) (139)
High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. (2004) (139)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. (2004) (136)
Adrenal cholesterol uptake from plasma lipoproteins: regulation by corticotropin. (1976) (124)
Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C‐II (1992) (122)
Targeted Disruption of the Mouse Lecithin:Cholesterol Acyltransferase (LCAT) Gene (1997) (122)
Human lipoprotein lipase: the loop covering the catalytic site is essential for interaction with lipid substrates. (1992) (119)
Plasma Phospholipid Transfer Protein (1997) (118)
Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. (1999) (118)
Two-dimensional electrophoresis of human plasma apolipoproteins. (1984) (116)
Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. (2015) (115)
Study of ABCA1 function in transgenic mice. (2003) (114)
In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. (1993) (114)
Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. (1993) (113)
Bovine parathyroid hormone: amino acid sequence. (1970) (112)
Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. (1982) (109)
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M400396-JLR200 (2005) (108)
3-Hydroxy-3-methylglutaryl coenzyme A reductase: regulation of enzymatic activity by phosphorylation and dephosphorylation. (1978) (105)
Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides (1996) (102)
Effect of thyrocalcitonin on adenosine 3':5'-cyclic phosphate formation by rat kidney and bone. (1970) (102)
Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein. (1992) (100)
In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. (1992) (99)
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology (2018) (95)
Peroxisome Proliferator-activated Receptor β/δ Regulates Very Low Density Lipoprotein Production and Catabolism in Mice on a Western Diet* (2004) (95)
Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. (1995) (94)
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial (2016) (92)
Human parathyroid hormone: amino-acid sequence of the amino-terminal residues 1-34. (1972) (91)
Asymmetry in the Lipid Affinity of Bihelical Amphipathic Peptides (2008) (90)
Apolipoprotein E metabolism in normolipoproteinemic human subjects. (1984) (89)
Vitamin E dose-response studies in humans with use of deuterated RRR-alpha-tocopherol. (1998) (89)
Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. (1993) (88)
Hepatic ABCG5 and ABCG8 Overexpression Increases Hepatobiliary Sterol Transport but Does Not Alter Aortic Atherosclerosis in Transgenic Mice* (2004) (87)
Human lipoprotein lipase. Analysis of the catalytic triad by site-directed mutagenesis of Ser-132, Asp-156, and His-241. (1992) (87)
The amino acid sequence of porcine thyrocalcitonin. (1968) (87)
ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies (2012) (87)
Apolipoproteins and lipoproteins in human plasma: an overview. (1988) (83)
beta 2-Glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H. (1983) (83)
The E-box motif in the proximal ABCA1 promoter mediates transcriptional repression of the ABCA1 gene. (2002) (83)
Activation of the enzymic activity of hepatic lipase by apolipoprotein A-II. Characterization of a major component of high density lipoprotein as the activating plasma component in vitro. (1983) (82)
Isolation and characterization of apoLp-Gln-II (apoA-II), a plasma high density apolipoprotein containing two identical polypeptide chains. (1972) (82)
Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. (2006) (82)
ABCA1 Overexpression in the Liver of LDLr-KO Mice Leads to Accumulation of Pro-atherogenic Lipoproteins and Enhanced Atherosclerosis* (2006) (81)
Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. (1985) (80)
Nucleotide sequence and the encoded amino acids of human apolipoprotein A-I mRNA. (1984) (79)
The ABCA1 transporter functions on the basolateral surface of hepatocytes. (2002) (79)
Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. (2004) (78)
A molecular model of high density lipoproteins. (1974) (77)
Effect of exercise conditioning on plasma high density lipoproteins and other lipoproteins. (1980) (75)
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. (2015) (74)
Analysis of the apolipoprotein B gene and messenger ribonucleic acid in abetalipoproteinemia. (1986) (73)
New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. (2003) (73)
Regulation of liver 3-hydroxy-3-methylglutaryl-CoA reductase. (1981) (72)
Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. (2004) (71)
The familial hyperchylomicronemia syndrome. New insights into underlying genetic defects. (1991) (71)
Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. (1983) (71)
Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. (2011) (71)
Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. (1995) (70)
Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. (1996) (70)
The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia. (1985) (70)
In vitro and in vivo phosphorylation of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase and its modulation by glucagon. (1980) (69)
Structural studies on rabbit muscle glycogen synthase. I. Subunit composition. (1975) (68)
Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. (1989) (68)
Lipid-protein interactions in high density lipoproteins. (1974) (68)
The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter Published, JLR Papers in Press, May 1, 2004. DOI 10.1194/jlr.C400002-JLR200 (2004) (68)
Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited Published, JLR Papers in Press, October 23, 2006. (2007) (67)
Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. (1987) (67)
Amino acid sequence of human plasma apolipoprotein C-II from normal and hyperlipoproteinemic subjects. (1984) (67)
Comparative genome analysis of potential regulatory elements in the ABCG5-ABCG8 gene cluster. (2002) (67)
A deletion mutation in the ApoC-II gene (ApoC-II Nijmegen) of a patient with a deficiency of apolipoprotein C-II. (1988) (66)
Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis. (1993) (66)
Genetic polymorphism of human plasma apolipoprotein A-IV is due to nucleotide substitutions in the apolipoprotein A-IV gene. (1990) (65)
An approach to the management of hyperlipoproteinemia. (1986) (65)
Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. (1981) (65)
Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. (1997) (64)
Hepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoE-deficient mice. (1998) (64)
Human apolipoprotein A-I. Post-translational modification by fatty acid acylation. (1986) (64)
Identification of a novel in-frame translational stop codon in human intestine apoB mRNA. (1987) (63)
Metabolism of human apolipoproteins A-I and A-II: compartmental models. (1983) (62)
Presence of two forms of apolipoprotein B in patients with dyslipoproteinemia. (1983) (62)
Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier). (1982) (61)
In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. (2000) (61)
Phosphorylation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic activity by calcium-activated and phospholipid-dependent protein kinase. (1985) (61)
Two different allelic mutations in the lecithin-cholesterol acyltransferase gene associated with the fish eye syndrome. Lecithin-cholesterol acyltransferase (Thr123----Ile) and lecithin-cholesterol acyltransferase (Thr347----Met). (1992) (60)
Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis. (1982) (60)
Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency. (1988) (59)
Carboxyl-terminal Domain Truncation Alters Apolipoprotein A-I in Vivo Catabolism (*) (1995) (58)
Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. (1992) (58)
Characterization and regulation of reductase kinase, a protein kinase that modulates the enzymic activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. (1979) (58)
Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. (1997) (58)
Chapter 15 – Effectiveness of Diet and Drugs in the Treatment of Patients with Elevated Lp(a) Levels (1990) (58)
Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. (1992) (58)
Two different allelic mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in classic LCAT deficiency: LCAT (tyr83-->stop) and LCAT (tyr156-->asn). (1993) (57)
Identification of two separate allelic mutations in the lipoprotein lipase gene of a patient with the familial hyperchylomicronemia syndrome. (1991) (57)
Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. (1991) (57)
Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176----Thr) leads to abnormal heparin binding and loss of enzymic activity. (1990) (56)
Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. (2000) (56)
Apolipoprotein B synthesis in humans: liver synthesizes only apolipoprotein B-100. (1985) (56)
A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency. (1989) (55)
Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. (2003) (55)
cDNA cloning of human apoA-I: amino acid sequence of preproapoA-I. (1983) (55)
Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma. (1993) (54)
Functional characterization of a chimeric lipase genetically engineered from human lipoprotein lipase and human hepatic lipase. (1993) (54)
Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. (1987) (54)
Expression of apolipoprotein B mRNAs encoding higher- and lower-molecular weight isoproteins in rat liver and intestine. (1989) (54)
In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. (1992) (53)
Estimation of VLDL cholesterol in hyperlipidemia. (1985) (53)
In vivo metabolism of proapolipoprotein A-I in Tangier disease. (1987) (53)
Discrimination between RRR- and all-racemic-alpha-tocopherols labeled with deuterium by patients with abetalipoproteinemia. (1994) (53)
Transcriptional regulation of the human lipoprotein lipase gene in 3T3-L1 adipocytes. (1991) (53)
Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. (1993) (52)
Human apolipoprotein A-I isoprotein metabolism: proapoA-I conversion to mature apoA-I. (1985) (52)
Human apolipoprotein B (apoB) mRNA: identification of two distinct apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA containing a premature in-frame translational stop codon, in both liver and intestine. (1988) (52)
Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease). (1981) (52)
Homozygous hypobetalipoproteinemia: a disease distinct from abetalipoproproteinemia at the molecular level. (1988) (51)
Focus on high-density lipoproteins in reducing cardiovascular risk. (2004) (51)
Tissue-specific expression of apolipoprotein A-I (ApoA-I) is regulated by the 5'-flanking region of the human ApoA-I gene. (1988) (51)
LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. (2000) (51)
A novel missense mutation in the C-terminal domain of lipoprotein lipase (Glu410-->Val) leads to enzyme inactivation and familial chylomicronemia. (1994) (50)
An initiation codon mutation in the apoC-II gene (apoC-II Paris) of a patient with a deficiency of apolipoprotein C-II. (1989) (50)
Effect of pressure and ionic strength on the self-association of Apo-A-I from the human high density lipoprotein complex. (1978) (50)
Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice site selection. (1996) (48)
Lipoprotein abnormalities in primary biliary cirrhosis (1985) (48)
Effect of gangliosides and substrate analogues on the hydrolysis of nicotinamide adenine dinucleotide by choleragen. (1977) (48)
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease (2017) (48)
Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. (1991) (48)
Human plasma proapoA-I: isolation and amino-terminal sequence. (1983) (47)
Human apolipoprotein A-I and C-III genes reside in the p11----q13 region of chromosome 11. (1984) (47)
HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease (2007) (46)
Isolation and characterization of the tryptic and cyanogen bromide peptides of apoLp-Gln-II (apoA-II), plasma high density apolipoprotein. (1972) (46)
Effects of nitrogen mustard on protein and nucleic acid synthesis in mouse fibroblasts growing in vitro. (1961) (46)
Genetic polymorphism of apolipoprotein A-IV (1991) (46)
New features of the national cholesterol education program adult treatment panel III lipid‐lowering guidelines (2003) (46)
Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics (1991) (45)
The lipid-laden foam cell: an elusive target for therapeutic intervention. (2000) (45)
Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. (1996) (45)
Three genetic variants of human plasma apolipoprotein A-IV. apoA-IV-1(Thr347----Ser), apoA-IV-0(Lys167----Glu,Gln360----His), and apoA-IV-3(Glu165----Lys). (1991) (45)
Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. (1996) (44)
Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. (2009) (43)
NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. (1983) (43)
The ABCA1 Transporter Modulates Late Endocytic Trafficking INSIGHTS FROM THE CORRECTION OF THE GENETIC DEFECT IN TANGIER DISEASE* □ S (2004) (43)
Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome (2014) (42)
Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein. (1993) (42)
Apolipoprotein A-I isoforms in human lymph: effect of fat absorption. (1983) (42)
A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. (2004) (42)
Identification of low density lipoprotein receptor binding domains of human apolipoprotein B-100: a proposed consensus LDL receptor binding sequence of apoB-100. (1986) (42)
Distinct hepatic receptors for low density lipoprotein and apolipoprotein E in humans. (1985) (41)
Human plasma apolipoproteins A-IV-0 and A-IV-3. Molecular basis for two rare variants of apolipoprotein A-IV-1. (1990) (40)
Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. (2004) (40)
Tangier disease: a structural defect in apolipoprotein A-I (apoA-I Tangier). (1982) (40)
Lipoprotein lipase: structure, function and mechanism of action (1994) (40)
Human preproapolipoprotein C-II. Analysis of major plasma isoforms. (1986) (40)
Recent studies on the chemistry of human, bovine and porcine parathyroid hormones. (1974) (40)
Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. (1984) (40)
In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism. (1994) (39)
Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. (1994) (39)
The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice* (2004) (39)
Intracellular trafficking of the free cholesterol derived from LDL cholesteryl ester is defective in vivo in Niemann-Pick C disease: insights on normal metabolism of HDL and LDL gained from the NP-C mutation. (1997) (39)
The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter (2004) (39)
Cellular Localization and Trafficking of the Human ABCA 1 Transporter * (2001) (38)
The thermodynamics of the self-association of the reduced and carboxymethylated form of apo-a-II from the human high density lipoprotein complex. (1976) (37)
Isolation and alignment of the tryptic peptides of alanine apolipoprotein, an apolipoprotein from human plasma very low density lipoproteins. (1974) (36)
Novel Therapies Focused on the High-Density Lipoprotein Particle (2014) (36)
Lipoprotein lipase correlates positively and hepatic lipase inversely with calcific atherosclerosis in homozygous familial hypercholesterolemia. (1997) (36)
Amino acid sequence of bovine thyrocalcitonin. (1969) (36)
Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes (1992) (35)
Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. (1992) (35)
Phosphorylation and modulation of the enzymic activity of native and protease-cleaved purified hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase by a calcium/calmodulin-dependent protein kinase. (1987) (34)
Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. (1997) (34)
The human apolipoprotein A-II gene is located on chromosome 1. (1984) (34)
Ocular manifestations of familial high-density lipoprotein deficiency (Tangier disease). (1979) (33)
The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia. (1986) (32)
Tangier disease. The complete mRNA sequence encoding for preproapo-A-I. (1985) (32)
Abnormal low density lipoprotein metabolism in apolipoprotein E deficiency. (1986) (32)
HDL: structure, function and metabolism. (1991) (32)
Analysis of the apoC-II gene in apoC-II deficient patients. (1984) (31)
Self-association of apo-C-I from the human high density lipoprotein complex. (1977) (31)
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. (2016) (31)
Characterization of the plasma lipoproteins and apoproteins of the Erythrocebus patas monkey. (1976) (31)
31P nuclear magnetic resonance spectroscopy of native and recombined lipoproteins. (1974) (31)
Absence of triglyceride accumulation in lipoprotein lipase-deficient human monocyte-macrophages incubated with human very low density lipoprotein. (1993) (31)
Homozygous familial hypobetalipoproteinemia. Increased LDL catabolism in hypobetalipoproteinemia due to a truncated apolipoprotein B species, apo B-87Padova. (1996) (30)
Characterization of plasma lipids and lipoproteins in patients with beta 2-glycoprotein I (apolipoprotein H) deficiency. (1985) (30)
Relative biologic activities of human and bovine parathyroid hormones and their synthetic, NH2-terminal (1-34) peptides, as evaluated in vitro with renal cortical adenylate cyclase obtained from three different species. (1976) (30)
The human apolipoprotein A-II gene: complete nucleic acid sequence and genomic organization. (1985) (29)
In Vitro Expression of Structural Defects in the Lecithin-Cholesterol Acyltransferase Gene (*) (1995) (29)
Human ApoB-100 gene resides in the p23----pter region of chromosome 2. (1985) (29)
Purification and characterization of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase from chicken liver (1977) (29)
Human apolipoprotein C-II: complete nucleic acid sequence of preapolipoprotein C-II. (1984) (29)
Vitamin A and vitamin E replacement in abetalipoproteinemia. (1984) (29)
The self-association of apoA-II, an apoprotein of the human high density lipoprotein complex. (1975) (29)
Distribution of subclasses of HDL containing apoA-I without apoA-II (LpA-I) in normolipidemic men and women. (1994) (28)
Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. (1992) (28)
Transport of apolipoproteins A-I and A-II by human thoracic duct lymph. (1981) (28)
Correction of hypoalphalipoproteinemia in LDL receptor-deficient rabbits by lecithin:cholesterol acyltransferase. (1998) (27)
Apolipoprotein EBethesda Isolation and partial characterization of a variant of human apolipoprotein e isolated from very low density lipoproteins (1984) (26)
The molecular behavior of apoA-I in human high density lipoproteins. (1975) (26)
ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. (1996) (26)
A First-inMan , Randomized , Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome (26)
Apolipoprotein C‐ll deficiency syndrome due to apo C‐IIHamburg: clinical and biochemical features and Hphl restriction enzyme polymorphism (1992) (26)
Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). (1995) (26)
Familial HDL deficiency due to marked hypercatabolism of normal apoA-I. (1993) (26)
Characterization of neutral and acid ester hydrolase in Wolman's disease. (1982) (26)
Adrenocortical function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin). (1987) (25)
In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study. (1994) (25)
Separation of apolipoprotein B species by agarose-acrylamide gel electrophoresis. (1986) (25)
The heart in Tangier disease. Severe coronary atherosclerosis with near absence of high-density lipoprotein cholesterol. (1992) (24)
Human Lecithin:Cholesterol Acyltransferase Deficiency: In Vivo Kinetics of Low-Density Lipoprotein and Lipoprotein-X (2006) (24)
The composition and metabolism of high density lipoprotein subfractions (1979) (24)
Effect of low density lipoproteins, high density lipoproteins, and cholesterol on apolipoprotein A‐I mRNA in Hep G2 cells (1989) (24)
Apolipoprotein E expression by human-monocyte-derived macrophages. Modulation by opsonised zymosan and cholesterol. (1990) (23)
Delayed low density lipoprotein (LDL) catabolism despite a functional intact LDL-apolipoprotein B particle and LDL-receptor in a subject with clinical homozygous familial hypercholesterolemia. (1998) (23)
Lipoproteins containing apolipoprotein B isolated from patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia: identification and characterization. (1995) (23)
Human proapoA-ITangier: isolation of proapoA-ITangier and amino acid sequence of the propeptide. (1983) (23)
Aneurysmal coronary artery disease in cerebrotendinous xanthomatosis. (1988) (23)
Lipids, Apolipoproteins and Lipoproteins (1994) (23)
Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mices⃞ Published, JLR Papers in Press, October 27, 2006. (2007) (22)
Isolation and chemical properties of porcine thyrocalcitonin. (1968) (22)
Neomycin and plasma lipoproteins in type II hyperlipoproteinemia (1984) (22)
The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. (1974) (21)
The localization of the gene for apolipoprotein C-II to chromosome 19. (1984) (20)
3. Genetic (primary) forms of hypertriglceridemia (1991) (20)
In vivo modulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reductase kinase, and reductase kinase kinase by mevalonolactone. (1984) (20)
Human plasma apolipoprotein C-II: total solid-phase synthesis and chemical and biological characterization. (1987) (19)
Developmental Regulation of Apolipoprotein B mRNA Editing Is an Autonomous Function of Small Intestine Involving Homeobox Gene Cdx1* (2003) (19)
The human apoB-100 gene: apoB-100 is encoded by a single copy gene in the human genome. (1987) (19)
Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. (1995) (19)
The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease (2011) (19)
The self-association of the reduced ApoA-II apoprotein from the human high density lipoprotein complex. (1975) (18)
Massive omental reticuloendothelial cell lipid uptake in Tangier disease after splenectomy. (1983) (18)
A comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or anti-apoB reporting antibodies. (1994) (17)
Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects. (2002) (17)
Metabolic syndrome: the dysmetabolic state of dysfunctional adipose tissue and insulin resistance (2008) (17)
Analysis of the mixed association between human apolipoproteins A-I and A-II in aqueous solution. (1980) (16)
In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II. (2002) (16)
Characterization of single base substitutions in edited apolipoprotein B transcripts. (1989) (16)
Sicca-like syndrome in type V hyperlipoproteinemia. (1980) (16)
A conformational study of porcine thyrocalcitonin. (1970) (15)
Counter-current chromatography of lipoproteins with a polymer phase system using the cross-axis synchronous coil planet centrifuge. (1992) (15)
Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high-density lipoproteins. (1996) (15)
Evaluation of the mixed interaction between apolipoproteins A-II and C-I equilibrium sedimentation. (1981) (15)
Molecular genetics of apoC-II and lipoprotein lipase deficiency. (1991) (15)
The molecular biology of human apoA-I, apoA-II, apoC-II and apoB. (1986) (14)
Identification of sequence homology between human plasma apolipoprotein B-100 and apolipoprotein B-48. (1986) (14)
Human apolipoprotein A-l and A4 metabolism (1982) (14)
Comparison of six pharmacologic regimens for hypercholesterolemia. (1987) (14)
Hemoglobin switching in sheep and goats. 3. Cell-free initiation of sheep globin synthesis. (1974) (14)
Effects of nitrogen mustard on the physicochemical properties of mouse fibroblast deoxyribonucleic acid. (1963) (14)
Apolipoprotein C-II deficiency: identification of a structural variant ApoC-II Padova. (1988) (13)
Identification and management of heterozygous familial hypercholesterolemia: summary and recommendations from an NHLBI workshop. (1993) (13)
Impaired adrenal reserve in the Watanabe Heritable Hyperlipidemic rabbit: implications for LDL-receptor function in steroidogenesis. (1985) (13)
Identification of an apoC-II variant (apoC-IIBethesda) in a kindred with apoC-II deficiency and type I hyperlipoproteinemia. (1988) (13)
Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia. (1985) (13)
The chemical ionization mass spectrometric analysis of phenylthiohydantoin and 2-anilino-5-thiazolinone amino acids obtained from the Edman degradation of proteins and peptides. (1980) (13)
Apolipoprotein A-I isoprotein synthesis by the perfused rat liver. (1982) (13)
Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I: A-II and LpA-IV particles from plasma. (1993) (13)
Genetic (primary) forms of hypertriglyceridemia. (1991) (13)
The interaction of apoA-I from human high density lipoprotein with lysolecithin. (1975) (12)
Workshop on apolipoprotein quantification. (1983) (12)
13C nuclear magnetic resonance spectroscopy of native and recombined lipoproteins. (1974) (12)
Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.M400020-JLR200 (2004) (12)
Human hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: evidence for the regulation of enzymic activity by a bicyclic phosphorylation cascade. (1984) (12)
Modulation of rat liver 3-hydroxy-3-methylglutaryl-CoA reductase activity by reversible phosphorylation. (1982) (12)
ApoE deficiency: markedly decreased levels of cellular ApoE mRNA. (1986) (11)
Enhanced apolipoprotein E production with normal hepatic mRNA levels in the Watanabe heritable hyperlipidemic rabbit. (1988) (11)
Total solid-phase synthesis, purification, and characterization of human parathyroid hormone-(1-84). (1983) (11)
In vivo protein metabolism utilizing stable isotopes and mass spectrometry: a new approach to the study of mutant proteins in humans. (1990) (11)
The use of parenteral hyperalimentation and elemental formula feeding in the treatment of Wolman disease (1985) (11)
Apolipoprotein A-I metabolism in subjects with a PstI restriction fragment length polymorphism of the apoA-I gene and familial hypoalphalipoproteinemia. (1990) (11)
Apolipoprotein E Modulates the Metabolism of Apolipoprotein B Containing Lipoproteins by Multiple Mechanisms (1989) (11)
Automated Edman degradations: studies with a large sequencer cup and high-speed drive. (1979) (10)
Editorial: Osteoclastic bone resorption and the hypercalcemia of cancer. (1974) (10)
New Challenges for HDL-Modifying Therapies as a Strategy to Lower Cardiovascular Disease Events in Statin-Treated Patients (2015) (9)
MR Virtual Angioscopy of Thoracic Aortic Atherosclerosis in Homozygous Familial Hypercholesterolemia (2001) (9)
Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations. (2002) (9)
Purification and characterization of apolipoprotein C-II from human plasma by high-pressure liquid chromatography. (1982) (8)
Clinical significance of plasma lipid levels. (1989) (8)
Analysis of reversible lipoprotein-cell interactions. (1982) (8)
Petar Alaupovic: The father of lipoprotein classification based on apolipoprotein composition. (2014) (8)
3-Hydroxy-3-methylglutaryl coenzyme A reductase from avian liver. Catalytic properties. (1979) (8)
A naturally occurring mutation at the second base of codon asparagine 43 in the proposed N-linked glycosylation site of human lipoprotein lipase: in vivo evidence that asparagine 43 is essential for catalysis and secretion. (1994) (8)
APOLIPOPROTEIN E ALLELES IN SEVERE HYPERTRIGLYCERIDAEMIA (1983) (8)
2P-0451 The ABCA1 transporter modulates late endocytic trafficking (2003) (7)
Type III hyperlipoproteinemia: Quantification, distribution, and nature of atherosclerotic coronary arterial narrowing in five necropsy patients. (1981) (7)
Vitamin E dose-response studies in humans with use of deuterated RRR-a-tocopherol 1 – 3 (7)
Isolation and immunological characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase from human liver. (1982) (7)
Isolation and characterization of bovine thyrocalcitonin. (1970) (7)
Current concepts of the molecular structure and metabolism of human apolipoproteins and lipoproteins (1981) (7)
Comparative evaluation of fibric acid derivatives and HMG-CoA reductase inhibitors (1992) (7)
Chemistry and Conformation of the Bovine Parathyroid Hormone (1972) (7)
Risk factors for the development of premature cardiovascular disease. (1985) (7)
Human Lipoprotein Lipase (2001) (7)
Solubilization of 3-hydroxy-3-methylglutaryl coenzyme A reductase from rat and chicken liver microsomes. (1978) (6)
Low-Density Lipoprotein Receptor and Apolipoprotein A-I and B Expression in Human Enterocytes (2003) (6)
Clinical Features, Lipoprotein Characterization, Lipase Activity, and Correction of Hypertriglyceridemia after Apolipoprotein C-Il Administration in Two Affected Patients (1986) (6)
Characterization of high density lipoprotein-bound and soluble RT6 released following administration of anti-RT6.1 monoclonal antibody. (1998) (6)
Studies on Glycogen Synthase and Its Control by Hormones (1974) (6)
Amino acid sequence of human plasma apolipoprotein C-III from normolipidemic subjects. (1986) (5)
Upregulated synthesis of both apolipoprotein A-I and apolipoprotein B in familial hyperalphalipoproteinemia and hyperbetalipoproteinemia. (1998) (5)
An improved system for the separation and identification of phenylthiohydantoin derivatives of histidine and arginine by thin-layer chromatography. (1976) (5)
ATVB In Focus Role of ABCA1 in Cellular Cholesterol Efflux and Reverse Cholesterol Transport (2003) (4)
The Role of HDL-C in the Management of Atherosclerosis (2015) (4)
Human Apolipoprotein Mutants 2 (1989) (4)
The molecular defects in lipoprotein lipase deficient patients (1992) (4)
Left atrial endocardial lipid deposits and absent to minimal arterial lipid deposits in familial hyperchylomicronemia. (1991) (4)
Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preβ-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia. (2020) (3)
Human proapolipoprotein A-I: development of an antibody to the propeptide as a probe of apolipoprotein A-I biosynthesis and processing. (1987) (3)
Complete genomic sequence of the human ABCA1 gene: analysis of the human (2001) (3)
Recent advances in lipoprotein metabolism and the genetic dyslipoproteinemias. (1991) (3)
Apolipoprotein A-IMilano: In Vivo Metabolism of an Apolipoprotein A-I Variant (1986) (2)
Role of HDL in reverse cholesterol transport (1994) (2)
Apo C-IIPadova: A New Apoprotein Variant in Two Patients with Apo C-II Deficiency Syndrome (1986) (2)
Prospects and Future Challenges Translation of High-Density Lipoprotein Function Into Clinical Practice: Current (2013) (2)
Biosynthesis and post-transcriptional modifications of plasma apolipoproteins (1990) (2)
Homozygous hypobetalipoproteinemia: transcriptional regulation and 5'-flanking sequence analysis in an apolipoprotein B deficiency state. (1989) (2)
Overexpression of human lecithin-cholesterol acyl transferase in transgenic rabbits leads to hyperalphalipoproteinemia (1994) (2)
CHAPTER 4 – High-Density Lipoprotein Metabolism (2009) (2)
AHA Conference Report on Cholesterol. Diagnosis, evaluation, and treatment: current status and issues. (1989) (2)
VLDL ApoB-100 and ApoE Metabolism in Male and Female Subjects Utilizing the Stable Isotope Technique (1993) (2)
In Vivo Catabolism of Apolipoprotein A-I in Subjects with Familial Hypoalphalipoproteinemia (1989) (2)
1.P.77 Correction of hypoalphalipoproteinemia in LDL receptor deficiency by lecithin: cholesterol acyltransferase (LCAT) (1997) (2)
Lcat overexpression in different animal models: modulation of atherosclerosis by CETP, HL and apoA-1 (1999) (2)
[Genetic variants of apo E: significance for triglyceride metabolism]. (1991) (2)
Parathyroid Hormone: Structure and Immunoheterogeneity (1975) (2)
4.P.362 Lecithin: Cholesterol acyltransferase (LCAT) knockout mice: A new animal model for human LCAT-deficiency (1997) (1)
A cyclic proteolytic reaction around photosystem II at the inside of the thylakoid membrane in DCMU‐poisoned chloroplasts (2001) (1)
New insights into the role of HDL in reverse cholesterol transport and atherosclerosis (1999) (1)
Current Concepts of the Plasma Lipoproteins and Their Role in Atherosclerosis (1995) (1)
Role of Gene Therapy in the Treatment of the Genetic Dyslipoproteinemias (1996) (1)
The Management of Hyperlipoproteinemia-Reply (1986) (1)
Human plasma apolipoprotein CII : Total solid-phase synthesis and chemical and biological characterization ( lipoprotein lipase ) (1)
Recent Studies on the Metabolic Defect in Tangier Disease (1986) (1)
P5355Impact of evacetrapib on glyvemic control: results from the accelerate trial (2017) (1)
Human apolipoprotein mutants III : diagnosis and treatment (1993) (1)
2nd International Symposium on Triglycerides and HDL (2005) (1)
Human Apolipoprotein A-IV (1993) (1)
Lipid-Protein Interactions in High Density Lipoproteins ( recombination of apolipoproteins with phospholipids / circular dichroism and gel chromatography of recombined lipid-protein particles ) (1)
DextranSulfate-Mg2 Precipitation Procedure forQuantitation of High- Density-Lipoprotein Cholesterol (1982) (1)
Abstract 19342: The Impact of PCSK9 Inhibitors on Lipid Levels and Outcomes in Patients With Primary Hypercholesterolemia: A Network Meta-analysis (2015) (1)
Intravascular ultrasound analysis to determine the relationship between high-density lipoprotein cholesterol and lesion characteristics in patients with coronary artery disease. (2014) (1)
High-Density Lipoprotein Metabolism (2011) (1)
The LDL receptor is not required for normal catabolism of Lp(a) in humans (1994) (1)
Gene therapy for the genetic dyslipoproteinaemias (1995) (1)
Editorial to:BStatin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High Density Lipoprotein^ by E.J. Niesor et al. (2015) (0)
New Insights into the Role of HDL in the Development of Cardiovascular Disease (1998) (0)
3-Hydroxy-3-methylglutaryl coenzyme A reductase : Regulation of enzymatic activity by phosphorylation and dephosphorylation ( enzyme regulation / covalent modification / cholesterol biosynthesis ) (0)
4.P.363 Two novel mutations of cholesteryl ester transfer protein (CETP) gene in Japanese hyperalphalipoproteinemic patients (1997) (0)
In Vivo Metabolism of a Mutant Apolipoprotein A-I (ARG-26) Associated with Hereditary Amyloidosis (1991) (0)
Heterogeneityof LipoproteinElectrophoreticPatternsin PatientswithType HaHyperlipoproteinemia (2004) (0)
In vitro activation of the enzymic activity of hepatic lipase by apo‐A‐II (2001) (0)
A novel domain enzyme missense mutation in the C-terminal of lipoprotein lipase (GIu410+Val) leads to inactivation and familial chylomicronemia (1994) (0)
Immunoblot Analysis of the Different Apolipoprotein B Species (1986) (0)
In vivo kinetics of a mutant protein, APO A-I IOWA (1992) (0)
Workshop IV: Diagnosis, evaluation, and treatment: Current status and issues (1989) (0)
Type III hyperlipoproteinemia: A quantitative study demonstrating severe diffuse coronary artery narrowing by atherosclerotic plaques including frequent severe narrowing of the left main (1982) (0)
The Mutations of Apolipoprotein B Gene Causing Hypobetalipoproteinemia: Molecular and Functional Abnormalities in Apo B-87Padova (1993) (0)
A new dawn in the treatment of dyslipidemia: cardiovascular risk reduction through emerging science and proven clinical results. Introduction. (2004) (0)
2.P.100 The in vivo of metabolism of free-Apo(a) in normals and subjects with abetalipoproteinemia (1997) (0)
The Molecular Basis of Genetic Defects in HDL Metabolism (1993) (0)
Recent Studies on the Molecular Defect in Apolipoprotein E Deficiency (1986) (0)
The Role of Apolipoprotein E and the Low-Density Lipoprotein Receptor in Modulating the in Vivo Metabolism of Apolipoprotein-B-Containing Lipoproteins (1987) (0)
Cellular Localization and Trafficking of the Human ABCA1 Transporter*□S (2001) (0)
Tu-PL2:1 HDL structure and metabolism as related to cardiovascular disease (2006) (0)
Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin. (1988) (0)
Characterization of a Ca/sup 2 +/, calmodulin-dependent protein kinase which is able to phosphorylate native and protease cleaved purified hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase (1986) (0)
Mechanisms involved in the modulation of hepatic 3 hydroxy 3 methyl glutaryl coenzyme a reductase in intact rats by mevalono lactone (1983) (0)
0.S.7 Gene targets for treatment of cardiovascular disease (1997) (0)
4WS26-1 The role of ABC transporters in atherosclerosis; Studies in transgenic mouse models (2003) (0)
Expression of apolipoprotein B mRNAs encoding higher- and lower-molecular weight isoproteins in rat liver and intestine (0)
Human Plasma Apolipoproteins A-IV-O and A-IV-3 (2001) (0)
Abstract 1692: The Impact of Hypertriglyceridemia on Clinical Outcome of Patients Subjected to Percutaneous Coronary Intervention in the Presence of High and Low High-Density Lipoprotein Cholesterol (2008) (0)
4MP05 Treatment of dyslipoproteinemia in the 21st century: Potential targets for new drug development (2003) (0)
Meeting Summary Workshop on Apolipoprotein Quantification (2005) (0)
ATP Binding Cassette A1 Transporter Function and Tangier Disease (2010) (0)
Changes in ATP III focus on diabetes and the metabolic syndrome. (2002) (0)
Post-Translational Modification by Covalent Phosphorylation of Human Apolipoprotein B-100 (1995) (0)
Transgenic mice expressing human lecithin-cholesterol acyltransferase (LCAT) (1995) (0)
Isolation of Novel Genes Regulated by Dietary Cholesterol by a Pcr-Based Subtraction Library (1995) (0)
Peptides with multiple amphipathic-helical domains and procedures for use. (2005) (0)
Mevinolin and Neomycin in the Treatment of Type II Hyperlipoproteinemia (1987) (0)
The Molecular Basis of ApoC-II Deficiency (1989) (0)
The role of apolipoproteins, receptors, and enzymes in genetic models of HDL metabolism and atherosclerosis (1999) (0)
Modulation of human apolipoprotein a i messenger rna by mevinolin and low density lipoproteins (1985) (0)
We-W38:1 The role of various structural motifs of HDL-mimetic peptides in cholesterol efflux by the ABCA1 transporter (2006) (0)
Impaired in vivo metabolism of HDL in familial hypercholesterolemia (1993) (0)
Translational and post-translational processing in apolipoprotein metabolism. (1988) (0)
2P-0446 Structural features of amphipathic helical peptides that promote lipid efflux (2003) (0)
The Role of HDLC in the Management of Atherosclerosis Moderated (2012) (0)
4.P.388 Relative importance of apoE in cholesterol efflux (1997) (0)
Th-W57:5 Decreased plasma apoB-containing lipoprotein and atherosclerosis in ABCG5/G8 X LDLR-KO mice on ezetimibe (2006) (0)
Phosphorylation and modulation of enzymic activity of native and protease cleaved purified hepatic 3-hydrox-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase by a calcium, calmodulin-dependent kinase (1987) (0)
Effects of Chenodeoxycholic Acid (CD) Treatment on Endogenous Plasma Triglyceride (TG) Transport in Hyperlipoproteinemia (HLP) (1978) (0)
Amino Acid Sequence of Human apoLp-Gln-II ( apoA-II ) , an Apolipoprotein Isolated from the High-Density Lipoprotein Complex ( pyrrolidone carboxylic acid / lipid-protein interactions / human blood plasma / automated Edman degradations / protein structure ) (0)
4.P.267 Human lecithin: cholesterol acyltransferase deficiency: In vivo LpX kinetics and its cell association with various cells (1997) (0)
CETP , Lipoprotein Metabolism , and Atherosclerosis in Humans Genetic CETP Deficiency in Humans and Effects on Lipoprotein Metabolism (2003) (0)
Only in the Presence of Normal LDL Receptors in Transgenic Rabbits LCAT Modulates Atherogenic Plasma Lipoproteins and the Extent of Atherosclerosis (2000) (0)
Phosphorylation and Modulation of Enzymic Activity of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase by Multiple Kinases (1989) (0)
Genomic Structure, Biosynthesis, and Processing of Preproapolipoprotein C-II (1987) (0)
LB-OR-4 SELECTIVE DELIPIDATION OF HDL IN PLASMA PRODUCES PRE-BETA HDL EFFECTIVE IN REVERSE CHOLESTEROL TRANSPORT IN VIVO IN MONKEYS (2007) (0)
3P-0791 Roles of cubilin and megalin in apolipoprotein A-I renal catabolism in the cubilin dysfunctional canine model (2003) (0)
HDL Infusion Therapy (2010) (0)
Kinetics of apolipoproteins A-I and A-II (1984) (0)
Amphipathic helical multi-domain peptides and methods for their application (2005) (0)
Role of CETP in the Development of Atherosclerosis in Animals Expression of CETP in Transgenic Mice (2003) (0)
NEW INsIGHTS INTO THE ROLE OF HDL IN THE DEVELOPMENT OF CARDIOVASCULAR (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With H. Bryan Jr. Brewer?

H. Bryan Jr. Brewer is affiliated with the following schools: